Toray Industries, Inc. and Toray Medical Co., Ltd. announced that Canadian Authority, Health Canada has issued an Interim Order for use of an endotoxin adsorption cartridge, TORAYMYXIN® to treat patients with the novel coronavirus (“COVID-19”).
COVID-19, the novel coronavirus (SARS-CoV-2) is an infectious disease that causes organ dysfunction including respiratory failure with worsening disease conditions. As the COVID-19 pandemic accelerates,“Interim order respecting the Importation and sale of medical devices for use in relation to COVID-19” has been established by Health Canada.
Toray has possessed the Canadian Import License for TORAYMYXIN® to treat patients with septic shock since its approval in 2003 (License Number: 63404). In addition to the current indications, Toray applied for the authorization of the interim order for TORAYMYXIN® to treat COVID-19 patients, and was granted expanded indications for use on April 17 as follows.
Expanded indications for the interim order
When TORAYMYXIN is used for COVID-19 patients, indications are as follows:
Acute respiratory failure in the absence of cardiac failure or fluid overload
Having diffuse alveolar damage (DAD) (HRCT findings)
PaO2/FiO2 =< 300 mmHg
Copyright © acrofan All Right Reserved
TECH
[CES 2021] LG Emphasized "Needs to Innovate Beyond..
[CES 2021] Sony Unveiled Its Latest Initiatives Sur..AUTO
Macan sets new standards: the first all-electric S..
Putting the new Macan through its paces in the nam..GAME
G-Star 2019 : Global Game Exhibition for the Whole..
2019 LoL Champions Korea Spring Media DayMedia
DISNEY+ Showcases Ambitious New Content Slate from..
eCommerce leader Coupang Dives into Video Streamin..